ResMed Inc.

NYSE:RMD

Medical - Devices

Healthcare
$242.61 +0.85%

+$1.58 today

Market cap
$34.12B
Beta
0.78
P/E (TTM)
18.1
EPS (TTM)
$10.37
Dividend yield
1.28%
52W Low $180.27High $293.81

Volume 1.22M

Average 1.32M

RMD Net Income

Bottom-line profit, the starting point for calculating cash from operations.

ResMed Inc.NYSE: RMD

Net Income · Q4 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q4 FY2026 net income of $1.52B rose 301.2% year over year, ahead of the +90.1% change in trailing-twelve-month net income. Sequentially, it rose 282.0% from the prior quarter. Over 3 fiscal years it compounded at +19.3% a year.

Context

  • Net income amounted to 26.9% of revenue in FY2026, down 0.3 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 22 analysts of $1.76B (+15.7%) for the fiscal year ending Jun 2027, a step up from the +8.8% reported in FY2026.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.52B+282.0% QoQ
Last fiscal yearJun 2026
$1.52B+8.8% YoY
LTMJun 2026
$2.66B+90.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+301.2%+10.5%-290.6 pp
1 year+8.8%+15.7%+6.9 pp
3-year CAGR+19.3%+9.0%-10.3 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2026
1.52B USD
Year-over-year change
+8.8%
4-year CAGR
+18.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How RMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +90.1% is the 3rd highest of 9, against a peer median of +23.6%.
  • Net income amounts to 47.1% of revenue for RMD, versus a peer median of 14.1%.
RMD Competitors
Net Income for RMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$5.27B USD+12.7%+8.5%14.0%
BSXBoston Scientific CorporationLTM Jun 2026$3.67B USD+34.6%+60.6%17.5%
ISRGIntuitive Surgical, Inc.LTM Sep 2026$2.97B USD+7.4%+28.9%25.6%
RMDResMed Inc.LTM Jun 2026$2.66B USD+90.1%+19.3%47.1%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$2.04B USD-12.0%+3.4%10.1%
PHGKoninklijke Philips N.V.LTM Jun 2026€1.12B EUR+541.7%—6.3%
TFXTeleflex IncorporatedLTM Jun 2026$320.9M USD-267.2%-45.6%12.3%
INSPInspire Medical Systems, Inc.LTM Jun 2026$135.04M USD+154.2%—15.0%
ELMDElectromed, Inc.LTM Mar 2026$10.1M USD+41.1%+48.4%14.1%
Peer median (excluding RMD) —+23.6%+18.7%14.1%

Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Net Income779.44M897.56M1.02B1.4B1.52B
Depreciation & Amortization193.84M197.56M216.21M235.81M244.15M
Deferred Income Tax0216K000
Stock-Based Compensation65.26M71.14M80.18M91.66M104.35M
Change in Working Capital(708.08M)(462.13M)44.78M16.74M(74.24M)
Accounts Receivables19.35M(106.51M)(134.28M)(76.68M)(96.78M)
Inventory(311.68M)(248.83M)172.2M(80.17M)(9.92M)
Accounts Payables(247.63M)31.34M090.96M172.72M
Other Working Capital(168.11M)(138.13M)6.86M82.63M(140.26M)
Other Non-Cash Items20.69M(11.05M)39.13M6.66M8.28M
Operating Cash Flow351.15M693.3M1.4B1.75B1.81B
Capital Expenditures(156.04M)(134M)(114.86M)(89.87M)(156.29M)
Acquisitions (Net)(42.78M)(1.01B)(133.46M)(139.25M)(350.72M)
Purchases of Investments(20.72M)(32.23M)(22.46M)(6.42M)(28.54M)
Sales of Investments6.8M3.94M1M02.75M
Other Investing Activities(17.18M)15.2M(15.4M)35.48M(12.41M)
Investing Cash Flow(229.92M)(1.16B)(269.78M)(200.05M)(545.2M)
Debt Repayment122M665M(730M)(40M)(10M)
Common Stock Issued47.38M49.14M53.09M74.44M74.5M
Common Stock Repurchased00(150.01M)(300.03M)(700.04M)
Dividends Paid(245.34M)(258.28M)(282.32M)(310.88M)(349.66M)
Other Financing Activities(52.41M)(32.99M)(10.05M)(29.79M)(21.83M)
Financing Cash Flow(128.36M)422.87M(1.12B)(606.25M)(1.01B)
Effect of Forex Changes(14.43M)(2.15M)(1.72M)25.8M6.18M
Net Change in Cash(21.57M)(45.82M)10.47M971.09M259.78M
Free Cash Flow195.11M559.3M1.29B1.66B1.65B

ResMed Inc.

NYSE:RMD

Intrinsic Alpha fair value

Locked

Current Price

$242.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.